OhmBody's Neuro-Wearable Aims to Reboot Menstrual Wellness at CES

SAN FRANCISCO, CA – January 02, 2026 – As the tech world descends on Las Vegas for CES 2026, a new wearable is poised to capture attention by tackling one of the most underserved areas in consumer health: menstrual wellness. OhmBody, the women’s wellness division of neurostimulation leader Spark Biomedical, will debut its first device, a science-informed wearable designed to offer a holistic, drug-free approach to the entire menstrual cycle. The launch marks a significant entry into the booming femtech market, blending cutting-edge neuroscience with a user-centric design.

Set to exhibit at Booth #55432, OhmBody is not another period tracker or simple pain relief gadget. It represents a new category of menstrual care that views the monthly cycle as a 'whole-body experience' shaped by the nervous system. The technology aims to move beyond merely masking symptoms like cramps and instead support the body’s overall well-being, addressing a wide spectrum of experiences from mood and stress to digestion and sleep.

A New Frontier in Menstrual Health

At the core of OhmBody's innovation is its unique ability to be the first consumer wearable to simultaneously engage two critical cranial nerve pathways: the vagus and trigeminal nerves. This dual-stimulation approach is designed to work with the body’s natural communication networks rather than overriding them.

The device itself consists of a small, handheld control unit connected by a thin cable to a discreet earpiece. Through this earpiece, it delivers gentle, noninvasive neurostimulation. The company explains that this process helps guide the nervous system from a stressed 'fight or flight' (sympathetic) state, often exacerbated during menstruation, towards a calmer 'rest and digest' (parasympathetic) state. By promoting this autonomic balance, OhmBody aims to holistically improve comfort, energy levels, emotional regulation, and even gastric distress associated with the menstrual cycle.

“OhmBody was created around a simple idea: you shouldn’t have to stop living your life because your period starts,” said Amy Gaston, VP of Strategic Growth at OhmBody, in a statement. “CES is an important moment for us to show how clinically informed technology can support menstrual wellness by working with the nervous system in a way that fits into real, everyday life.”

The Science Behind the Signal

The company’s claims are not just theoretical. OhmBody’s parent company, Spark Biomedical, has grounded the device in a growing body of clinical research. A peer-reviewed pilot study published in Frontiers in Medicine on October 14, 2025, provided the first human trial data for transcutaneous auricular neurostimulation (tAN) in menstrual health. The study, though small with 16 participants, yielded promising results.

Participants using the device reported statistically significant, favorable differences compared to their baseline cycles. Key findings included an average reduction in menstrual blood loss of approximately 54-57%, a nearly 20% shorter menstrual duration, and a 45% reduction in gastric discomfort. Furthermore, clinical trial data noted that 88% of participants experienced greater menstrual comfort and 71% felt more emotionally stable. These results suggest a potential for neurostimulation to offer more than just pain management, aligning with OhmBody’s whole-body wellness mission.

The scientific premise is rooted in the known functions of the targeted nerves. The vagus nerve is a superhighway of the nervous system, influencing digestion, heart rate, and mood. The trigeminal nerve is crucial for sensory processing and neurochemical signaling. By gently stimulating both, OhmBody seeks to create a systemic effect that helps the body self-regulate through the hormonal and physiological shifts of the menstrual cycle.

Navigating the Booming Femtech Market

OhmBody enters a dynamic and rapidly expanding femtech market, projected to reach nearly $100 billion by 2030. While the space includes menstrual cycle tracking apps and pain relief devices, OhmBody carves out a distinct niche. Existing non-pharmacological solutions, such as TENS (Transcutaneous Electrical Nerve Stimulation) devices like Livia, primarily focus on blocking abdominal pain signals. OhmBody’s approach is fundamentally different, targeting the root of systemic dysregulation in the nervous system via the brain's own pathways.

This premium positioning is reflected in its price. The OhmBody Starter Kit is set to retail for $719, which includes the device and initial supplies. The single-use adhesive earpieces will represent an ongoing cost for users, placing it市场 at the higher end of the consumer wellness spectrum. This strategy targets consumers seeking science-backed, non-invasive, and hormone-free alternatives to traditional medication and who are willing to invest in a long-term wellness solution.

Institutional Backing and the Path to Approval

A significant factor lending credibility to OhmBody's ambitious launch is the institutional backing of its parent company. In August 2025, Spark Biomedical was awarded a major grant from Wellcome Leap, a global health innovation initiative backed by the Wellcome Trust. Spark was one of only 13 organizations worldwide, and the only non-research institution, selected for 'The Missed Vital Sign' program, which aims to accelerate R&D in women's health.

The funding is specifically earmarked to support a large-scale, decentralized pivotal clinical trial for OhmBody's tAN technology in treating heavy menstrual bleeding (HMB). The ultimate goal of this trial is to generate the robust clinical data necessary to seek full regulatory approval from the U.S. Food and Drug Administration (FDA). This is a crucial point for consumers: while OhmBody is launching at CES as a wellness device, it is on a clear path toward becoming a clinically validated, FDA-cleared medical device. This long-term strategy sağlık its commitment to scientific rigor and separates it from many wellness gadgets that lack a pathway to medical validation.

Spotlight on CES 2026

At CES, OhmBody's debut is timed perfectly with the show's increasing emphasis on digital health. The event now features dedicated conference tracks and summits on wearables and women's health, signaling a shift from general fitness gadgets to serious medical and wellness technologies. Amy Gaston is also scheduled to participate in a panel discussion titled “The Data-Powered Lifespan: Digital Health Solutions Tailoring Care for Every Woman’s Life Stage,” further cementing the company's position as a thought leader in the space.

Attendees visiting the OhmBody booth will have the opportunity for live demonstrations and one-on-one conversations with the team, offering a firsthand look at the technology. By showcasing its clinical findings alongside its consumer-friendly design, OhmBody aims to bridge the gap between complex neuroscience and everyday user experience, presenting a compelling case for a new era in menstrual care.